InflaRX develops highly specific monoclonal antibodies targeting activation products of the complement system for application in life-threatening inflammatory diseases. InflaRX’s approach is to focus on specific C5a inhibitors as C5a is a key player in many acute and chronic inflammatory processes. InflaRX has made breakthrough discoveries in the area of anti-C5a antibody generation, resulting in a new class of highly selective antibodies with exception blocking activities, and the company’s first-in-class antihuman C5a monoclonal antibody is currently in development.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.